Abstract
The unfavourable epidemic situation and epidemic-related government spending on the medical and pharmaceutical sectors provided added momentum to the growth of the Russian pharmaceutical market in the first months of 2020. The government investments in the procurement of pharmaceutical and medical products as well as the implementation of the Pharma-2030 strategy will continue to be the main drivers of such growth in the medium and long term. Adopted back in April 2019, this strategy provides for a rising scale of expenditure on healthcare, further import substitution, the local content of products made in Russia by foreign multinationals, as well as the development of e-commerce in the pharmaceutical retail sector.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Remedium. Journal about the Russian market of medicines and medical equipment
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
